Blackhawk Growth Files Quarter Ended September 30, 2021 Financials and Reports Increase in Value of Its Portfolio by 165% Quarter Over Quarter

Blackhawk Growth Files Quarter Ended September 30, 2021 Financials and Reports Increase in Value of Its Portfolio by 165% Quarter Over Quarter

Vancouver, British Columbia – TheNewswire – November 29, 2021 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (the “Company”), is pleased to announce that the financial statements and MD&A for its first quarter ended September 30, 2021 have been filed on Sedar.

Highlights for the quarter ended September 30, 2021:

  • Blackhawk acquires MindBio Therapeutics Pyt Ltd., clinical stage drug development company that is pioneering psychedelic micro-dosing research and is advancing emerging therapies to treat a range of debilitating health conditions such as depression, anxiety, chronic pain, cognitive impairment and PTSD.
  • Spaced Food Inc. begins commercial production of it proprietary Astronaut Sorbet
  • Sac Pharma Partners Inc. continues to record record results and launches new proprietary strains
  • As at September 30, 2021, Blackhawk held $16,719,850 in current investments, a 165% increase from the value at June 30, 2021
  • As at September 30, 2021, NAV per share was $0.38

 

Blackhawk Growth Corp. (“Blackhawk” or the “Company”) continues to review both equity and debt investment opportunities. The Company has focused its investments in the health, cannabis and CBD industries, in both Canada and the US.

 

“Our acquisition of MindBio Therapeutics in the first quarter ending September 30, 2021 was a transformational step forward for Blackhawk. Our portfolio of companies continue to show growth and value to our shareholders as we work to execute, expand and deliver even more value to shareholders over the course of the year” says Frederick Pels, CEO of Blackhawk Growth Corp.

As at September 30, 2021 the Company’s equity investments consist of the following:

 

Company Cost Fair Value
SAC Pharma Partners Inc. $        1,890,000 $        1,890,000
Noble Line Inc.         986,800         986,800
Trip Pharma 997,644 997,644
NuWave Foods Inc. 783,892 783,892
Gaia Grow Corp. 1,050,000 900,000
Engine Media (UMG) 41,043 10,244
Fantasy Aces Daily Fantasy Sports Corp. 455,268 13,441
Spaced Food Inc. 311,191 311,191
MindBio Therapeutics 10,826,638 10,826,638
Total Equity Investments $        17,342,476 $        16,719,850

 

Short-term loans consist of the following:

 

September 30, 2021 June 30, 2021
Short term loans 259,609 259,609
Total loan investments $        259,609 $        259,609

 

About Blackhawk Growth

 

Blackhawk Growth is an investment holding looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food and NuWave Foods. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A

 

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

 

For more information on Blackhawk, please visit our website at:

https://www.blackhawkgrowth.com/

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

 

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the future prospects of the business of the Company and its portfolio companies. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Blackhawk Growth’s MindBio Therapeutics Advances Microdosing Clinical Trial to 59 Patients

Blackhawk Growth’s MindBio Therapeutics Advances Microdosing Clinical Trial to 59 Patients

Vancouver, British Columbia – TheNewswire – November 15, 2021 – Blackhawk Growth Corp. (CNSX:BLR) (OTC:BLRZF) (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that their wholly-owned subsidiary, MindBio Therapeutics Pty Ltd (“MindBio”), has reached a new milestone for its Phase 1 clinical trial microdosing LSD with 59 participants successfully completing the trial.  The clinical trial is the first and largest safety clinical trial of its kind anywhere in the world.

MindBio is a multi-disciplinary company pioneering new treatments for mental health conditions using psychedelic medicines, technology assisted mental health interventions and psychedelic assisted psychotherapies.

MindBio is on track to have its Phase 1 clinical trial in 80 healthy participants completed by April in 2022.  In this unique study, trial participants are prescribed the drug by a doctor and take it home with them in the same way they would take an anti-depressant medication.  Clinical trial participants are assessed on a comprehensive range of psychometric and biometric markers to determine safety and efficacy of the drug.

LSD is a psychoplastogen, which is a fast-acting class of therapeutics, capable of rapidly promoting structural and functional neural plasticity and shows potential for treating diseases in psychiatry1. Microdosing involves patients taking a small amount of the medicine on a regular basis.  In larger doses, LSD is a hallucinogenic drug that changes cognition and perception, however in much smaller “microdoses”, the medicine is subperceptual, meaning that patients can take the drug without noticing its hallucinogenic effects, but still receive the medicinal benefit and get on with their normal day.

“This is extremely exciting work” says Frederick Pels, CEO of Blackhawk Growth Corp. “Our clinical trial is paving the way forward to create a class of new medicines that propose novel and effective solutions for treating serious mental illness. MindBio continues to demonstrate how its exceptional team of clinicians and engineers are dedicated to building products that can have a significant impact on people’s lives. I look forward to updating shareholders as developments continue to progress.”

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149016/

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Blackhawk Growth’s MindBio Therapeutics Completes Safety Milestone In Its Phase 1 Clinical Trials

Blackhawk Growth’s MindBio Therapeutics Completes Safety Milestone In Its Phase 1 Clinical Trials

Vancouver, British Columbia – TheNewswire – November 08, 2021 – Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that its wholly owned subsidiary, MindBio Therapeutics Pty Ltd (“MindBio”), has received feedback from the trial’s independent Data and Safety Monitoring Committee that the Phase 1 clinical trial is approved to continue after a successful six month safety review.

MindBio is a multi-disciplinary company pioneering new treatments for mental health conditions using psychedelic medicines, technology assisted mental health interventions and psychedelic assisted psychotherapies.

MindBio is currently undertaking the world’s first clinical trial of its kind microdosing LSD to 80 healthy participants who take the drug at home in the same way that they would take any other medication. MindBio is also targeting Major Depressive Disorder and distress in late-stage cancer patients in its Phase 2 trials which are currently in development and will follow next year.

The approval to continue Phase 1 clinical trials microdosing LSD after the independent safety review is a positive milestone achieved with more than 50% of the participants having now completed the trial.

“We are very pleased to report these safety outcomes in our clinical trials,” said Frederick Pels, CEO of Blackhawk Growth Corp. “These results showcase the caliber of work we are doing, targeting more effective medical treatments for mental health conditions. Throughout these trials, MindBio is solidifying its position as a market leader in the psychedelic research sector. We look forward to updating shareholders with further developments in the near future.”

 

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

New advisor supports expansion into psychedelic treatments

BLACKHAWK GROWTH APPOINTS NEW ADVISOR TO SUPPORT EXPANSION INTO PSYCHEDELICS AND MENTAL HEALTH TREATMENTS

Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) is accelerating its expansion into psychedelic and mental health treatments with a new addition to its team.

Yesterday, Blackhawk appointed Dr. Lahiru Russell, the founder and chief scientist of Digital Health Technologies, as the company’s medical advisor. Using her 10+ years of experience in clinical trials and psycho-oncology research, Dr. Russel is developing a mindfulness-based intervention platform that will help patients regulate their emotions and thoughts to reduce negative mental health conditions.

Blackhawk’s subsidiary, MindBio Therapeutics, will be able to utilize Dr. Russel’s IP in its microdosing research through a commercialization agreement with Digital Mind Technology, which was established last month.

MindBio will also utilize Google Cloud’s “Health Care Solutions” to recruit, enroll, and engage with patients in its internal clinical trials and to accelerate drug development.

PDF of article

Managing pain across the globe

BLACKHAWK GROWTH’S MINDBIO THERAPEUTICS BRINGS DIGITAL MENTAL HEALTH TECHNOLOGY TO PSYCHEDELICS CLINICAL TRIALS

Could microdosing + this new technology reduce pain in cancer patients?

MindBio Therapeutics is developing a technology platform to integrate with psychedelic therapy to prevent the mental health of cancer patients from deteriorating.

By utilizing wearable devices, the platform is designed to help with pain management to prevent depression, existential distress and anxiety.

MindBio Therapeutics will use the mindfulness app in an upcoming  Phase 2 microdosing trial, which is funded by the New Zealand government, to see if it provides additional benefits to late-stage cancer patients compared to microdosing alone.

The company aims to commercialize the application globally and believes the tech has potential to receive government funding in Europe.

PDF of article

Microdosing research expands worldwide!

Wake Network, Inc. Receives Certificate of Drug Registration for Microdose Formulation in Jamaica

Yesterday, Wake Network Inc received a Certificate of Drug Registration from the Jamaican Ministry of Health & Wellness for PSIL428, its microdose formulation made from natural psilocybin.

The certification allows the company to run clinical trials on anxiety and depression and makes PSIL429 available to clinics and academic institutions across the globe. Any country with a special access program can request to import the legal formulation for patient use.

In other microdosing news, MindBio Therapeutics, a subsidiary of Blackhawk Growth Corp. (BLR), is partnering with Trip Pharma’s LeichtMind clinic to launch microdosing clinical trials in Canada!

PDF of article 1

PDF of article 2